BRIEF published on 01/19/2026 at 07:35, 2 months 5 days ago FDA Reviews Advicenne's Sibnayal® for U.S. Approval FDA Advicenne Sibnayal® DRTA PDUFA Date
BRIEF published on 01/19/2026 at 07:35, 2 months 5 days ago Advicenne: FDA-approved marketing application for Sibnayal® FDA ATRd Advicenna Sibnayal® PDUFA
PRESS RELEASE published on 01/19/2026 at 07:30, 2 months 5 days ago Inside Information / Other news releases FDA accepts Advicenne's Marketing Authorization Application for Sibnayal® for dRTA treatment in the US, with a PDUFA decision target date of September 3rd, 2026 FDA Advicenne Sibnayal DRTA PDUFA
BRIEF published on 01/12/2026 at 07:35, 2 months 12 days ago Renewal of the marketing authorization for Sibnayal® in the European Union Kidney Disease EMA Advicenna AMM Sibnayal®
BRIEF published on 11/04/2025 at 11:35, 4 months 20 days ago Advicenne submits Sibnayal® to the US FDA FDA Advicenna Sibnayal® Renal Tubular Acidosis Registration Filing
PRESS RELEASE published on 11/04/2025 at 11:30, 4 months 20 days ago Inside Information / Other news releases Advicenne submits registration application for Sibnayal® in dRTA treatment to US FDA, designated orphan drug. Evaluation process expected to take 12 months Advicenne Sibnayal® US FDA DRTA Treatment Registration Application
BRIEF published on 09/19/2025 at 18:05, 6 months 5 days ago Advicenne: Half-year results in 2025 and outlook Financial Results Outlook Turnover United States Sibnayal®
BRIEF published on 07/28/2025 at 07:35, 7 months 27 days ago Advicenne Secures Marketing Authorization for Sibnayal® in Saudi Arabia Saudi Arabia Advicenne Reimbursement Sibnayal® DRTA
PRESS RELEASE published on 07/28/2025 at 07:30, 7 months 27 days ago Inside Information / Other news releases Advicenne obtains marketing authorization and reimbursement for Sibnayal® in Saudi Arabia, a fixed combination for rare kidney diseases, in collaboration with Taïba Healthcare Saudi Arabia Advicenne Reimbursement Marketing Authorization Sibnayal
BRIEF published on 07/25/2025 at 07:35, 7 months 30 days ago Advicenne Announces 9% Revenue Growth for H1 2025 Growth Turnover Advicenna Sibnayal® Pharmaceutical Markets
Published on 03/24/2026 at 23:00, 1 hour 2 minutes ago Redwood AI Selected to Present at BIO-Europe Spring 2026, Europe's Largest Springtime Biotech Partnering Event
Published on 03/24/2026 at 18:55, 5 hours 7 minutes ago Norse Gold Announces Closing of Private Placement Financing and Pending Reactivation on the TSX-V
Published on 03/24/2026 at 13:30, 10 hours 32 minutes ago GGL Resources Corp. Announces Closing of Earn-In Agreement with Nelson Resources Limited on Its Gold Point High-Grade Gold-Silver Project, Nevada
Published on 03/24/2026 at 13:30, 10 hours 32 minutes ago Innodata Announces Date of Annual Shareholder Meeting
Published on 03/24/2026 at 19:49, 4 hours 13 minutes ago EEII AG: Cancellation of the Extraordinary General Meeting of March 26, 2026
Published on 03/24/2026 at 19:41, 4 hours 20 minutes ago ASMALLWORLD Honoured with Regional Virtuoso Award in Continental Europe for “Most Engaged Member” in Recognition of Their Exceptional Contribution
Published on 03/24/2026 at 19:05, 4 hours 57 minutes ago WBS Power Advances 3.2 GW Energy Infrastructure for Hyperscale Data Center Campus
Published on 03/24/2026 at 18:39, 5 hours 22 minutes ago EQS-Adhoc: FORTEC Elektronik Aktiengesellschaft: Adjustment of the earnings forecast for the financial year 2025/2026
Published on 03/24/2026 at 18:00, 6 hours 2 minutes ago Cham Swiss Properties places bond of CHF 100 million
Published on 03/24/2026 at 17:46, 6 hours 16 minutes ago NRJ GROUP - Press release annual results 2025
Published on 03/24/2026 at 17:16, 6 hours 46 minutes ago Avaibility of the 2025 Universal Registration Document
Published on 03/24/2026 at 10:58, 13 hours 4 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of February 28, 2026
